Skip to main content
. Author manuscript; available in PMC: 2015 Oct 7.
Published in final edited form as: Cell Metab. 2014 Sep 18;20(4):573–591. doi: 10.1016/j.cmet.2014.08.005

Figure 3. Weighing Mortality Risks and Benefits of Pioglitazone.

Figure 3

Age-adjusted mortality rates for the entire U.S. population were derived from published government statistics for 2010–2011. Potential effects of pioglitazone on mortality from cardiometabolic causes or certain cancers were approximated from published analyses. The mortality from hip fracture is more complex to estimate, as it is not a proximal cause of death but clearly carries mortality risk in the elderly. See text for details.